Vardenafil HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318973

CAS#: 224789-15-5

Description: Vardenafil, also known as BAY 38-9456, is a PDE5 inhibitor used for treating erectile dysfunction. Vardenafil's indications and contra-indications are the same as with other PDE5 inhibitors; it is closely related in function to sildenafil citrate (Viagra) and tadalafil (Cialis). The difference between the vardenafil molecule and sildenafil citrate is a nitrogen atom's position and the change of sildenafil's piperazine ring methyl group to an ethyl group. Tadalafil is structurally different from both sildenafil and vardenafil. Vardenafil's relatively short effective time is comparable to but somewhat longer than sildenafil's.

Chemical Structure

Vardenafil HCl
CAS# 224789-15-5

Theoretical Analysis

MedKoo Cat#: 318973
Name: Vardenafil HCl
CAS#: 224789-15-5
Chemical Formula: C23H34Cl2N6O4S
Exact Mass:
Molecular Weight: 561.523
Elemental Analysis: C, 49.20; H, 6.10; Cl, 12.63; N, 14.97; O, 11.40; S, 5.71

Price and Availability

Size Price Availability Quantity
25.0mg USD 450.0 2 Weeks
50.0mg USD 750.0 2 Weeks
100.0mg USD 1350.0 2 Weeks
Bulk inquiry

Related CAS #: 224789-15-5 (2HCl)   224785-90-4 (free)   330808-88-3 (HCl trihydrate)  

Synonym: BAY 38-9456; BAY-38-9456; BAY38-9456; Vardenafil HCl; Levitra; Staxyn; Vivanza

IUPAC/Chemical Name: 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one dihydrochloride


InChi Code: InChI=1S/C23H32N6O4S.2ClH/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28;;/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30);2*1H


Appearance: White to off-white crystalline powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 561.523 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Ashour AE, Rahman AF, Kassem MG. Vardenafil dihydrochloride. Profiles Drug Subst Excip Relat Methodol. 2014;39:515-44. doi: 10.1016/B978-0-12-800173-8.00009-X. Review. PubMed PMID: 24794912.

2: Gamidov SI, Iremashvili VV, Popova AIu. [Modernity in the treatment of erectile dysfunction: Levitra (vardenafil) in the form of oral dispersible tablet]. Urologiia. 2013 May-Jun;(3):102-4, 106. Review. Russian. PubMed PMID: 23987060.

3: Venhuis BJ, de Kaste D. Towards a decade of detecting new analogues of sildenafil, tadalafil and vardenafil in food supplements: a history, analytical aspects and health risks. J Pharm Biomed Anal. 2012 Oct;69:196-208. doi: 10.1016/j.jpba.2012.02.014. Epub 2012 Mar 8. Review. PubMed PMID: 22464558.

4: Sanford M. Vardenafil orodispersible tablet. Drugs. 2012 Jan 1;72(1):87-98. doi: 10.2165/11208270-000000000-00000. Review. PubMed PMID: 22191797.

5: Chung E, Broc GB. A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases. Expert Opin Pharmacother. 2011 Jun;12(8):1341-1348. doi: 10.1517/14656566.2011.584064. Review. PubMed PMID: 21548725.

6: Wang HY, Huang YF. [Vardenafil for refractory erectile dysfunction: the latest advances]. Zhonghua Nan Ke Xue. 2009 Nov;15(11):1035-8. Review. Chinese. PubMed PMID: 20218319.

7: Morales AM, Mirone V, Dean J, Costa P. Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence. Clin Interv Aging. 2009;4:463-72. Epub 2009 Dec 29. Review. PubMed PMID: 20054411; PubMed Central PMCID: PMC2801586.

8: Rice KR, Dean RC. Vardenafil: efficacy, tolerability and future directions. Expert Opin Drug Metab Toxicol. 2009 May;5(5):553-62. doi: 10.1517/17425250902884108 . Review. PubMed PMID: 19416089.

9: Mirone V, Fusco F, Rossi A, Sicuteri R, Montorsi F. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies. BJU Int. 2009 May;103(9):1212-7. doi: 10.1111/j.1464-410X.2008.08267.x. Epub 2008 Dec 8. Review. Erratum in: BJU Int. 2011 Apr;107(7):1166. PubMed PMID: 19154480.

10: Eardley I, Lee JC, Guay AT. Global experiences with vardenafil in men with erectile dysfunction and underlying conditions. Int J Clin Pract. 2008 Oct;62(10):1594-603. doi: 10.1111/j.1742-1241.2008.01852.x. Review. PubMed PMID: 18822030.

11: Reffelmann T, Kloner RA. Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2007 May;8(7):965-74. Review. PubMed PMID: 17472542.

12: Doggrell S. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? Int J Impot Res. 2007 May-Jun;19(3):281-95. Epub 2006 Dec 21. Review. PubMed PMID: 17183346.

13: Hong K, Jiang H. [Safety and tolerability of Vardenafil]. Zhonghua Nan Ke Xue. 2006 Sep;12(9):857-60. Review. Chinese. PubMed PMID: 17009542.

14: Sommer F. Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor. Expert Opin Drug Metab Toxicol. 2005 Aug;1(2):295-301. Review. PubMed PMID: 16922644.

15: Montorsi F, Salonia A, Briganti A, Barbieri L, Zanni G, Suardi N, Cestari A, Montorsi P, Rigatti P. Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience. Eur Urol. 2005 May;47(5):612-21. Epub 2005 Jan 26. Review. PubMed PMID: 15826752.

16: Doggrell SA. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Expert Opin Pharmacother. 2005 Jan;6(1):75-84. Review. PubMed PMID: 15709885.

17: Huang YR. [Vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy]. Zhonghua Nan Ke Xue. 2005 Jan;11(1):76-9. Review. Chinese. PubMed PMID: 15704689.

18: Eardley I. Vardenafil: a new oral treatment for erectile dysfunction. Int J Clin Pract. 2004 Aug;58(8):801-6. Review. PubMed PMID: 15372854.

19: Markou S, Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbalias G. Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports. Int J Impot Res. 2004 Dec;16(6):470-8. Review. PubMed PMID: 15229625.

20: Bischoff E. Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int J Impot Res. 2004 Jun;16 Suppl 1:S34-7. Review. PubMed PMID: 15224134.

Additional Information

Related CAS#
CAS#224789-15-5 (Vardenafil dihydrochloride);
CAS#224785-90-4 (Vardenafil free base).
CAS#330808-88-3 (Vardenafil hydrochloride trihydrate)